Devi SenGupta
Gilead Sciences (United States)(US)Gilead Sciences (France)(FR)
Publications by Year
Research Areas
HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, HIV-related health complications and treatments, COVID-19 Clinical Research Studies
Most-Cited Works
- → Remdesivir for 5 or 10 Days in Patients with Severe Covid-19(2020)1,431 cited
- → Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19(2020)1,265 cited
- → Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial(2017)390 cited
- → Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021(2021)357 cited
- → Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities(2004)274 cited
- → Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment(2015)184 cited